Immatics Biotechnologies GmbH
Paul-Ehrlich-Strasse 15
Tuebingen
D-72076
Germany
Tel: 49-7071-565125-0
Fax: 49-7071-565125-99
Website: http://www.immatics.net/
Email: info@immatics.com
64 articles about Immatics Biotechnologies GmbH
-
GSK has pulled out of its partnership focused on developing T-cell receptor therapeutics for solid tumors with Immatics, the German biotech revealed in its Q3 financial results published Thursday.
-
Immatics Announces Third Quarter 2022 Financial Results and Business Update
11/17/2022
Immatics N.V. provided a business update and reported financial results for the quarter ended September 30, 2022.
-
Immatics announced plans to raise about $110 million in a common stock offering following the release of promising early-stage data that supports its ACTengine technology platform.
-
Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
9/10/2022
Immatics N.V. announced a comprehensive preclinical data set for its T cell engaging receptor product candidate IMA402 at the European Society for Medical Oncology Congress 2022 held in Paris, France, from September 9 to 13, 2022.
-
89bio presented positive data for pegozafermin in SHTG, Tonix enrolled its first patient with Long COVID for TNX-102, Belite enrolled patients with STGD1 and more clinical trial news.
-
The combination of Opdivo plus Yervoy in addition to chemotherapy demonstrated additional benefits in patient populations who usually have poor prognoses.
-
Immatics Announces First Quarter 2022 Financial Results and Business Update
6/2/2022
Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, reported financial results and provided a business update for the quarter ended March 31, 2022.
-
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
-
Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors
5/10/2022
Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced the initiation of a Phase 1 clinical trial with its T cell engaging receptor IMA401 for patients with recurrent and/or refractory solid tumors.
-
Bristol Myers Squibb is dropping $920 million to acquire the exclusive global rights of Immatics' experimental cancer drug program, the companies announced Tuesday morning.
-
BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions
7/7/2021
BioCopy AG announces a collaboration with Immatics N.V. "Immatics" in the field of characterization of T cell receptors.
-
Immatics Announces Changes to its Board of Directors - May 26, 2021
5/26/2021
Tuebingen, Germany and Houston, Texas, May26, 2021 – Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced changes to its Board of Directors.
-
Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME
5/11/2021
Immatics’ second TCR Bispecifics program IMA402 demonstratestumor cell killing in vitro and complete regressions of established tumors in anin vivo tumor model
-
The next several years will be transformative in the cell and gene therapy space, and Immatics’ Chief Medical Officer Cedrik M. Britten believes his company’s engineered T-cell receptors may play an important role in providing treatment options for cancer patients.
-
BioSpace Global Roundup, Aug. 20
8/20/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
BioSpace Movers & Shakers, June 5
6/5/2020
Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers. -
Immatics Appoints Cedrik Britten as Chief Medical Officer
6/4/2020
Former Head of Oncology Cell Therapy Research Unit at GSK to lead clinical development at Immatics
-
T cell redirecting cancer company Immatics Biotechnologies entered into a merger agreement with Arya Sciences Acquisition Corp. that will give the Germany-based company a listing on the Nasdaq exchange under the ticker symbol IMTX.
-
Immatics Announces Business Combination with Arya Sciences Acquisition Corp., Creating a Publicly Listed Leader in TCR-based Immunotherapies
3/17/2020
Upon successful completion of the business combination, Immatics will receive up to approximately $148 million of cash held within Arya’s trust account
-
Immatics and GSK Partner to Develop Novel Adoptive Cell Therapies
2/20/2020
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced it has entered into a strategic collaboration agreement with GSK to develop novel adoptive cell therapies targeting multiple cancer indications.